{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:08:54Z","timestamp":1763035734527},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1053\/beha.2002.0229","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T18:13:53Z","timestamp":1046801633000},"page":"639-652","source":"Crossref","is-referenced-by-count":23,"title":["Risk-adapted treatment according to minimal residual disease in adult ALL"],"prefix":"10.1053","volume":"15","author":[{"given":"Nicola","family":"G\u00f6kbuget","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kneba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Raff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Bruggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Scheuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Reutzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beha.2002.0229_RF1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF2","first-page":"540","article-title":"New approaches in acute lymphoblastic leukemia in adults: where do we go?","volume":"27","author":"Hoelzer","year":"2000","journal-title":"Seminars in Oncology"},{"key":"10.1053\/beha.2002.0229_RF3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukaemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to the protocols of theGerman Multicenter Study Group for Adult ALL (GMALL)","volume":"14","author":"G\u00f6kbuget","year":"2000","journal-title":"Hematology Oncology Clinics of North America"},{"key":"10.1053\/beha.2002.0229_RF5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0950-3536(05)80201-X","article-title":"Immunophenotypic classification of acute lymphoblastic leukaemia","volume":"7","author":"Ludwig","year":"1994","journal-title":"Bailliere's Clinical Haematology"},{"key":"10.1053\/beha.2002.0229_RF6","first-page":"802a","article-title":"Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05\/93 (abstract)","volume":"98","author":"G\u00f6kbuget","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF7","first-page":"732a","article-title":"Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): early results from the international ALL trial (MRC UKALL\/ECOG E2993)","volume":"94","author":"Rowe","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1999.01365.x","article-title":"Investigation of minimal residial disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis","volume":"105","author":"Foroni","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0229_RF9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(00)00418-6","article-title":"Minimal residual disease in leukaemia patients","volume":"2","author":"Szczepanski","year":"2001","journal-title":"Lancet Oncology"},{"key":"10.1053\/beha.2002.0229_RF10","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","article-title":"Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia","volume":"87","author":"Brisco","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF11","first-page":"1331a","article-title":"Evaluation of minimal residual disease (MRD) by competitive quantitative PCR using IgH\/TCR rearrangements has prognostic value in adult acute lymphoblastic-leukaemia (ALL): a single center study","volume":"98","author":"Preudhomme","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0229_RF13","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.1998.16.12.3774","article-title":"Prognostic value of immunophenotypic detection of minimal residual disease in acute lyphoblastic leukemia","volume":"16","author":"Ciudad","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0229_RF14","first-page":"700a","article-title":"Minimal residual disease in adult patients with acute lymphoblastic leukemia during the first year of therapy predicts clinical outcome","volume":"1","author":"Brueggemann","year":"2001","journal-title":"Hematology Journal"},{"key":"10.1053\/beha.2002.0229_RF15","first-page":"314a","article-title":"The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia (abstract)","volume":"98","author":"Brueggemann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF16","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/sj.leu.2400841","article-title":"Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response","volume":"11","author":"Foroni","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF17","first-page":"695a","article-title":"Risk stratification in childhood acute lymphoblastic leukemia based on clone-specific detection of minimal residual disease (MRD) with molecular genetics: performance in German Trial ALL-BFM 2000","volume":"1","author":"Schrappe","year":"2001","journal-title":"Hematology Journal"},{"key":"10.1053\/beha.2002.0229_RF18","first-page":"584a","article-title":"Clinical impact of minimal residual disease (MRD) in trial design for adult ALL (abstract)","volume":"98","author":"Hoelzer","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF19","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF20","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia \u2013 results of the prospective multicenter LALA-94 trial","volume":"100(7)","author":"Dombret","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2002.3311a.x","article-title":"Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation","volume":"116","author":"Sanchez","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0229_RF22","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF23","first-page":"1630a","article-title":"Molecular evidence of a GVL effect in allogeneic transplant for acute lymphoblastic leukemia restricted to Ph-negative leukemia: post-transplant immuno-modulation performed according to molecular follow-up seems efficient only in this subset of patients","volume":"98","author":"Lewalle","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF24","first-page":"2470a","article-title":"Activity of the ABL-tyrosine kinase inhibitor Glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ALL) relapsing after allogeneic stem cell transplantation (allo-SCT)","volume":"98","author":"Ottmann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2401245","article-title":"Primers and protocols for standardized detection of minimal residual disease in acute lyphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletion as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia","volume":"13","author":"Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF26","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.leu.2402150","article-title":"BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation","volume":"15","author":"Lucio","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.leu.2401741","article-title":"BIOMED-1 Concerted Action report: flow cytometric characterization of CD7+cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)","volume":"14","author":"Porwit-MacDonald","year":"2000","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF29","first-page":"60","article-title":"Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: is the disease multifocal?","volume":"103","author":"Sykes","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0229_RF30","first-page":"762a","article-title":"Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy","volume":"98","author":"Scheuring","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1702096","article-title":"Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction","volume":"25","author":"Atta","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/beha.2002.0229_RF32","first-page":"477a","article-title":"PCR monitoring of minimal residual disease identifies good outcome in BCR\/ABL positive acute lymphoblastic leukemia (ALL): CALGB 8762","volume":"88","author":"Westbrook","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/sj.leu.2400567","article-title":"Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)","volume":"11","author":"Preudhomme","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF34","article-title":"Molecular evaluation of consolidation therapy and early allograft or autograft for BCR-ABL-positive adult acute lymphoblastic leukemia patients: a pilot study of EIGLE (European Intergroup of GIMEMA, French LALA and EORTC)","volume":"90","author":"Stryckmans","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF35","first-page":"96","article-title":"A prospective study of residual-disease monitoring of the ALL1\/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia","volume":"95","author":"Cimino","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF36","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","article-title":"Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes","volume":"12","author":"Pongers-Willemse","year":"1998","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2141.1997.3723186.x","article-title":"Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukemia","volume":"99","author":"Brisco","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0229_RF38","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF39","first-page":"329","article-title":"Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow","volume":"9","author":"van Rhee","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0229_RF40","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/blood.V99.12.4386","article-title":"Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0229_RF41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10428199809059247","article-title":"Detection of minimal residual disease: methods and relationship to outcome in T-lineage acute lymphoblastic leukemia","volume":"32","author":"Dibenedetto","year":"1998","journal-title":"Leukemia & Lymphoma"},{"key":"10.1053\/beha.2002.0229_RF42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJM199701303360510","article-title":"Silence of the leukemic clone","volume":"336","author":"Greaves","year":"1997","journal-title":"New England Journal of Medicine"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260290229X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260290229X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T06:47:41Z","timestamp":1704782861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169260290229X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S152169260290229X"],"URL":"https:\/\/doi.org\/10.1053\/beha.2002.0229","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}